Investors are turning to underrated stocks like Ardelyx and TScan Therapeutics for long-term success. Ardelyx focuses on GI tract drugs with promising revenue growth. TScan Therapeutics is advancing TCR-T therapies for cancer treatment. Both show potential despite stock price fluctuations and under-the-radar status in 2025.

Ardelyx’s revenue in Q2 surged 33% YoY to $97.7 million, led by IBSRELA and XPHOZAH sales. IBSRELA saw an 84% YoY increase to $65 million. Ardelyx raised its 2025 IBSRELA sales forecast to $250-$260 million. XPHOZAH, treating hyperphosphatemia, gained traction with $25 million in sales. Partnerships in Japan and China are expanding its reach.

TScan Therapeutics is developing TCR-T therapies to target cancer cells. ALLOHA Trial focuses on blood malignancies, while PLEXI-T Trial targets solid tumors. TScan aims for scalable and cost-effective therapies. With $218 million in cash, it can fund operations until Q1 2027. Positive trial results could position TScan as a significant player in immuno-oncology innovation.

Both Ardelyx and TScan Therapeutics are rated a consensus “Strong Buy” by Wall Street analysts. Ardelyx has an average price target of $11.36, while TScan Therapeutics has an average target of $8.57. Both stocks show strong upside potential, with TScan potentially climbing 460% from current levels.

Read more at Yahoo Finance: 2 Overlooked Stocks to Snap Up in 2025